News of the Pfizer COVID-19 vaccine's effectiveness has inspired hope around containing the coronavirus. But polls show that up to two-thirds of Americans say they are unlikely to get a vaccine.
Pfizer's CEO sold $5.6 million worth of stock on Monday. The company says the stock sale was made as part of a preset plan. But NPR found irregularities about when the CEO entered into that plan.
For five decades, NorthPoint Health & Wellness Center has confronted the ways disparities can hurt its patients' health. Community leaders say it's a model for cities facing similar struggles.
The $1.6 billion Novavax contract is one of several Operation Warp Speed agreements issued through a third party, Advanced Technology International, and that hadn't been released.
Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.
Katherine Standefer was uninsured and working as a hiking guide when diagnosed with a genetic heart condition. She chronicles her experience with an implanted heart device in Lightning Flowers.
Gen. Gustave Perna says as soon as the FDA deems a vaccine safe and effective, his team is ready to coordinate deployment of tens of millions of doses as early as next month.
Pfizer's COVID-19 vaccine is the first to have data showing that it exceeded the minimum effectiveness threshold set by the Food and Drug Administration for emergency use.
NPR's Mary Louise Kelly talks with Gen. Gustave Perna about overseeing the logistics of a coronavirus vaccine for the Trump administration's Operation Warp Speed program.
The Trump administration has been marked by a scaled-back federal investment and involvement in U.S. health care. Biden's team has plans to change that — even if Republicans retain Senate control.
Coronavirus cases are surging around the country. How will Joe Biden manage the pandemic differently, once he takes office in January? Expect a more centralized U.S. response plan, his team says.
Newly released COVID-19 vaccine contracts include weakened protections against potential price gouging. Several key federal contracts still haven't been disclosed by the government.
An unreleased CDC review obtained by NPR shows that lab officials knew an early coronavirus test kit had a high failure rate. They decided not to recall it and sent it to the nation's labs anyway.
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
